Clinical Trials on Local Metastatic Melanoma

Total 12871 results

DNA Therapeutics

Completed

DNA Repair Inhibitor & Irradiation on Melanoma (DRIIM)

Local Metastatic Melanoma

France
Mohammed M Milhem
Genentech, Inc.

Terminated

Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib (ML28604)

Melanoma | Metastatic Melanoma | BRAF-mutated Metastatic Melanoma | V600EBRAF-mutated Metastatic Melanoma

United States
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)

Terminated

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma

Metastatic Cancer | Metastatic Melanoma

United States
National Cancer Institute (NCI)

Terminated

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

Metastatic Uveal Melanoma | Metastatic Ocular Melanoma

United States
Morphotek

Terminated

A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma

Melanoma | Metastatic Melanoma | Advanced Melanoma | Malignant Metastatic Melanoma

United States
Delcath Systems Inc.

Active, not recruiting

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

Metastatic Uveal Melanoma | Metastatic Ocular Melanoma

United States
Lee's Pharmaceutical Limited

Recruiting

Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma

Local Progression or Metastatic Melanoma With Failed First-line Treatment

China
University of Michigan Rogel Cancer Center

Recruiting

Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)

Metastatic Melanoma | Liver Metastases | Melanoma, Mucosal | Melanoma, Ocular | Melanoma, Cutaneous

United States
Elizabeth Davis
Bristol-Myers Squibb

Terminated

Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression

Metastatic Melanoma | Advanced Melanoma | Metastatic Melanoma Stratified by MHC-II Expression

United States
The Belgian Society of Medical Oncology
Roche Pharma AG; Foundation Medicine; Sciensano

Recruiting

A Study to Examine the Value of Broad Agnostic Next Generation Sequencing (NGS) Panel Testing Versus Reimbursed Organ-directed NGS: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Center

Metastatic Cancer | Local Tumor Invasion

Belgium
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study

Melanoma | Metastatic Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Recurrent Metastatic Melanoma

United States
Dermatologic Cooperative Oncology Group

Unknown

Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma

Metastatic Melanoma

Germany
GlaxoSmithKline

Withdrawn

Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma

Cancer | Metastatic Uveal Melanoma | GNA11 Mutation-positive Metastatic Melanoma | GNAQ Mutation-positive Metastatic Melanoma
Vastra Gotaland Region
Miltenyi Biomedicine GmbH

Recruiting

Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases (HAITILS)

Metastatic Cutaneous Melanoma | Metastatic Uveal Melanoma

Sweden
University Hospital, Montpellier

Recruiting

Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis

Metastatic Melanoma

France
Regeneron Pharmaceuticals
Bristol-Myers Squibb

Completed

CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

Melanoma | Metastatic Melanoma | Unresectable Melanoma | Advanced Melanoma

United States
Regeneron Pharmaceuticals
Bristol-Myers Squibb

Active, not recruiting

CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

Melanoma | Metastatic Melanoma | Unresectable Melanoma | Advanced Melanoma

United States
European Organisation for Research and Treatment...

Terminated

Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma

Metastatic Cancer | Intraocular Melanoma

Switzerland, Italy, United Kingdom, Poland
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma (JS001)

Metastatic Melanoma | Unresectable Melanoma

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma

Metastatic Melanoma | Advanced Melanoma

China
Craig L Slingluff, Jr
University of Virginia

Completed

Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists (MEL60)

Melanoma | Metastatic Melanoma | Mucosal Melanoma

United States
Ludwig Institute for Cancer Research
University of Chicago; University of Pittsburgh; Life Science Pharmaceuticals

Completed

Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma

Metastatic Melanoma | Cutaneous Melanoma

United States
Bristol-Myers Squibb

Completed

Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma (CheckMate 069)

Metastatic Melanoma | Unresectable Melanoma

United States, France
Cancer Trials Ireland

Completed

A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma (SYS-ACT)

Metastatic Melanoma | Advanced Melanoma

Ireland
Dana-Farber Cancer Institute
Partner Therapeutics (PTx)

Withdrawn

Sargramostim (GM-CSF) + PD-1

Metastatic Melanoma | Unresectable Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
NewLink Genetics Corporation

Completed

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

Metastatic Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Turnstone Biologics, Corp.

Recruiting

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Metastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous Melanoma

United States
Herlev Hospital

Active, not recruiting

Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac) (NeoPepVac)

Non Small Cell Lung Cancer Metastatic | Malignant Melanoma, Metastatic | Bladder Urothelial Carcinoma, Metastatic

Denmark
Hasumi International Research Foundation

Active, not recruiting

IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma

Melanoma, Uveal Metastatic

Germany
Ohio State University Comprehensive Cancer Center
Bristol-Myers Squibb

Unknown

Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma

Lung Metastases | Liver Metastases | Recurrent Melanoma | Stage IV Melanoma | Tumors Metastatic to Brain

United States
NewLink Genetics Corporation

Terminated

Immunotherapy Study for Patients With Stage IV Melanoma

Metastatic Melanoma | Stage IV Melanoma

United States
Lynn E. Spitler, MD
Genentech, Inc.; Celgene Corporation

Completed

Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study (AbraxAvast)

Metastatic Malignant Melanoma

United States
Biocad

Recruiting

A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma (OCTAVA)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma Advanced

India, Russian Federation, Belarus
Steinar Aamdal

Terminated

Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma

Metastatic Malignant Melanoma

Norway
Eli Lilly and Company

Completed

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

Metastatic Malignant Melanoma

United States
Melanoma and Skin Cancer Trials Limited
University of Oxford; Trans Tasman Radiation Oncology Group

Active, not recruiting

Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma (WBRTMel)

Metastatic Melanoma

Norway, Australia, United Kingdom
Centre Hospitalier Universitaire de Nīmes

Completed

Circulating Tumor Cells and Melanoma: Comparing the EPISPOT and CellSearch Techniques

Metastatic Melanoma

France
Hadassah Medical Organization

Unknown

Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients

Metastatic Disease | High Risk HLA-A2+ Melanoma
Centre Hospitalier Universitaire Vaudois

Active, not recruiting

Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)

Metastatic Melanoma Naive to Immune Therapy in Metastatic Setting

Switzerland
Dana-Farber Cancer Institute
AstraZeneca

Withdrawn

Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Recurrent Metastatic Melanoma

United States
Dr. Ronnie Shapira

Not yet recruiting

Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma (MK3475-C01)

Metastatic Melanoma | Malignant Melanoma | Immunotherapy | Malignant Melanoma Stage IV | BRAF V600E
Pierre Fabre Medicament
Biotrial

Active, not recruiting

Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations

Melanoma | Metastatic Melanoma | Unresectable Melanoma | BRAF V600 Mutation

France
Pierre Fabre Medicament

Recruiting

A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients (TavieSkin)

Metastatic Melanoma | Melanoma (Skin) | BRAF V600 Mutation

Portugal
Pierre Fabre Medicament

Completed

Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors (OCEANI)

Melanoma | BRAF V600E Unresectable or Metastatic Melanoma | BRAF V600E Metastatic NSCLC

China
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Cancer

Unspecified Adult Solid Tumor, Protocol Specific | Melanoma (Skin)

United States
Vastra Gotaland Region

Completed

Surgery for Gastrointestinal Metastases of Malignant Melanoma - a Single Center Retrospective Cohort Study (SurgMelMet)

Melanoma Stage Iv | Melanoma Metastatic | Abdominal Tumor

Sweden
Institut Jean-Godinot
Université de Reims Champagne-Ardenne

Not yet recruiting

Association Between Helioderma and Response to Immunotherapy in Patients With Metastatic Melanoma (Helioma)

Metastatic Melanoma
Abramson Cancer Center at Penn Medicine
National Cancer Institute (NCI)

Recruiting

Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma (RadVax)

Metastatic Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

Metastatic Melanoma

United States
Centre Hospitalier Universitaire de Nice

Completed

Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes (EXOSOMES)

Metastatic Melanoma

France

Clinical Trials on Local Metastatic Melanoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations